Serina Therapeutics, Inc.
SERSerina Therapeutics, Inc. in brief
Serina Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Huntsville, Alabama, USA. Its market value was $50 M on 30 October 2026, which makes it the 21,260th largest listed company in the world and the 3,852nd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $19 M. It employs about 16 people. Its largest product and service lines by sales in 2025 were Grant revenues (100%). Its shares trade under the symbol SER (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Serina Therapeutics, Inc.
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection.
From the company's annual report filed with the US SEC: read the report
Serina Therapeutics, Inc. timeline
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2023
- 💰Record revenue of $3 millionFY2023, the highest of the 8 years on record.
- 2024
- ✎Renamed Serina Therapeutics, Inc.Formerly AgeX Therapeutics, Inc..
Events of Serina Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,855 (Oct 2026) · #3,856 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 386.3×
- Price / book
- —
- Free cash flow yield
- -35.9%
- Net margin
- -14753.8%
- Operating margin
- -18476.9%
- Return on equity
- —
- Liabilities / assets
- 100.6%
- Net debt
- $17M
- Revenue growth
- +116.7%
- R&D / revenue
- 10123.1%
- Revenue per employee
- $8 K
- Profit per employee
- $-1.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | +116.7% | $-24M | $-19M | -14753.8% |
| Dec 2024 | $0M | -98.1% | $-17M | $-11M | -18566.7% |
| Dec 2023 | $3M | +10400.0% | $-3M | $5M | 167.3% |
| Dec 2022 | $0M | -78.6% | $-7M | $-10M | -34866.7% |
| Dec 2021 | $0M | -61.1% | $-8M | $-9M | -6200.0% |
| Dec 2020 | $0M | -79.2% | $-10M | $-11M | -3016.7% |
| Dec 2019 | $2M | +23.6% | $-13M | $-12M | -702.3% |
| Dec 2018 | $1M | — | $-11M | $-8M | -535.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-18M | $0M | $-18M | $-1.91 | — |
| Dec 2024 | $-17M | $0M | $-17M | $-1.51 | — |
| Dec 2023 | $-2M | $1M | $-3M | $0.73 | — |
| Dec 2022 | $-6M | — | — | $-9.70 | — |
| Dec 2021 | $-8M | — | — | $-0.23 | — |
| Dec 2020 | $-8M | $0M | $-8M | $-0.29 | — |
| Dec 2019 | $-10M | $1M | $-11M | $-0.33 | — |
| Dec 2018 | $-8M | $0M | $-8M | $-0.21 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 9, 20268-KCurrent reportBylaws amended
- Sep 9, 20268-KCurrent reportOther events
- Aug 27, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Aug 24, 2026S-1IPO registration
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jul 23, 20268-KCurrent reportDirectors or officers changed
- Jul 22, 20268-KCurrent reportDirectors or officers changed
- Jun 24, 20268-KCurrent reportBylaws amended · Shareholder vote
- May 14, 20268-KCurrent reportResults of operations
Official filings of Serina Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-24 M
- Net income
- $-19 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $7 M
- Total equity
- $-0 M
As of December-2025
Top 28 institutional investors in Serina Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Sio Capital Management, LLC | 2,000,000 | +1,000,000 (+100.00%) | 7.53% | $4 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 184,703 | +22,505 (+13.88%) | 0.70% | $0 M | Nov 13, 2026 |
| 3 | Ashton Thomas Private Wealth, LLC | 88,888 | New | 0.33% | $0 M | Nov 3, 2026 |
| 4 | Waverly Advisors, LLC | 67,492 | 0 (0.00%) | 0.25% | $0 M | Nov 16, 2026 |
| 5 | Geode Capital Management, LLC | 32,203 | -18,804 (-36.87%) | 0.12% | $0 M | Nov 6, 2026 |
| 6 | Virtu Financial LLC | 22,596 | New | 0.09% | $0 M | Nov 17, 2026 |
| 7 | Northern Trust Corp | 20,771 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 8 | Vanguard Fiduciary Trust Co | 20,009 | 0 (0.00%) | 0.08% | $0 M | Nov 13, 2026 |
| 9 | Avidian Wealth Enterprises, LLC | 18,800 | 0 (0.00%) | 0.07% | $0 M | Oct 8, 2026 |
| 10 | State Street Corp | 12,758 | 0 (0.00%) | 0.05% | $0 M | Nov 12, 2026 |
| 11 | Keel Point, LLC | 10,809 | -10,699 (-49.74%) | 0.04% | $0 M | Nov 16, 2026 |
| 12 | Citigroup Inc | 5,230 | New | 0.02% | $0 M | Nov 4, 2026 |
| 13 | Caitong International Asset Management Co., Ltd | 3,682 | -62 (-1.66%) | 0.01% | $0 M | Oct 29, 2026 |
| 14 | Wells Fargo & Company/mn | 3,611 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 15 | Tower Research Capital LLC (TRC) | 3,075 | +505 (+19.65%) | 0.01% | $0 M | Nov 16, 2026 |
| 16 | BlackRock, Inc. | 2,378 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 17 | Osaic Holdings, Inc. | 2,002 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 18 | Royal Bank Of Canada | 1,000 | New | 0.00% | $0 M | Nov 16, 2026 |
| 19 | Morgan Stanley | 608 | +594 (+4242.86%) | 0.00% | $0 M | Nov 13, 2026 |
| 20 | Piscataqua Savings Bank | 28 | 0 (0.00%) | 0.00% | $0 M | Oct 21, 2026 |
| 21 | Albion Financial Group /ut | 8 | 0 (0.00%) | 0.00% | $0 M | Oct 21, 2026 |
| 22 | Pacifica Partners Inc. | 8 | 0 (0.00%) | 0.00% | $0 M | Oct 9, 2026 |
| 23 | UBS Group AG | 5 | -1,342 (-99.63%) | 0.00% | $0 M | Nov 10, 2026 |
| 24 | Barclays PLC | 4 | -541 (-99.27%) | 0.00% | $0 M | Nov 6, 2026 |
| 25 | Jpmorgan Chase & Co | 3 | +2 (+200.00%) | 0.00% | $0 M | Nov 12, 2026 |
Show all 28: investors 26 to 28
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | BNP Paribas Financial Markets | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 27 | Rockefeller Capital Management L.P. | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 28 | Farther Finance Advisors, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
Mutual funds holding Serina Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 125,805 | $0 M | 0.47% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 45,248 | $0 M | 0.17% | <0.01% | +56% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 33,331 | $0 M | 0.13% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 4,739 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 2,592 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 2,495 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Serina Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Stephen K. BrannanDirector | Buy | +1,000 | $2.030 | $2 K | 1,000 | Form 4 |
| filed | Gregory BaileyDirector | Conversion | +1.77 M | $2.250 | $4.0 M | 1.90 M | Form 4 |
| filed | Gregory BaileyDirector | Conversion | +6.67 M | $2.250 | $15.0 M | 8.56 M | Form 4 |
| filed | Jay VenkatesanDirector | Conversionindirect | +224,152 | $2.250 | $504 K | 231,705 | Form 4 |
| filed | Karen J. WilsonDirector | Buy | +5,000 | $1.770 | $9 K | 10,100 | Form 4 |
| filed | Karen J. WilsonDirector | Buy | +5,100 | $1.750 | $9 K | 5,100 | Form 4 |
| filed | Steven A. LedgerChief Executive Officer, Director | Grant or award | +10,100 | $1.930 | $19 K | 10,100 | Form 4 |
| filed | Jay VenkatesanDirector | Buy | +589 | $1.780 | $1 K | 589 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Serina Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-35.17 reverse split in the period to ; 1-for-35.21 reverse split
Trading halts
- 2025-09-09 19:12 UTC, code T3, resumed 20:00 UTC
- 2025-08-26 13:36 UTC, code M, resumed 13:41 UTC
Fails to deliver
- : 2,116 shares at $1.89
- : 44 shares at $1.64
- : 163 shares at $1.67
- : 4,994 shares at $1.71
- : 202 shares at $1.72
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Serina Therapeutics, Inc. scorecard#
Passes 1 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median386.3×Price to sales 386.3× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-35.9%Free cash flow is -35.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.91 vs -1.51Diluted EPS -1.91 in fiscal 2025 against -1.51 the year before (report's currency).
- ✗Net income higher than five years earlier-$19 M-$19 M in fiscal 2025 against -$11 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 2
- ✗Profitable in the newest year-$19 MNet income -$19 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.71 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-19.43Z-score -19.43 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year38.5%Diluted shares up 38.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Serina Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0.1+132%100% | 0.1−98.2%100% | 3.2r0.1+9174%100% | 0.0−76.4%100% | 0.1−60.1%100% | 0.4r1.9−79.1%100% | 1.7+23.8%100% | 1.4−0.6%100% | 1.4—100% | |
| Cost of revenue | — | — | 0.0+208%1.3% | 0.0−31.6%38.2% | 0.0−26.9%13.2% | 0.0r0.2−89.3%7.2% | 0.2−33.0%14.1% | 0.4+117%26.1% | 0.2—12.0% | |
| Gross profit | — | — | 0.1+386%3.2% | 0.0−83.2%61.8% | 0.1−62.7%86.8% | 0.3r1.7−77.4%92.8% | 1.5+43.8%85.9% | 1.0−16.5%73.9% | 1.2—88.0% | |
| Research and development | 13+75.9%10119% | 7.5+213%13357% | 2.4r0.7+133%75.7% | 1.0−29.6%3015% | 1.5−60.8%1011% | 3.7r5.0−37.1%1029% | 5.9+1.3%342% | 5.8+0.8%418% | 5.8—412% | |
| General and administrative | 11+14.3%8459% | 9.6+147%17186% | 3.9r9.3−34.8%124% | 6.0−11.0%17562% | 6.7−0.2%4658% | 6.7r7.4−17.4%1862% | 8.1+44.1%471% | 5.6+46.0%405% | 3.9—276% | |
| Operating expenses | 24+41.2%18578% | 17+172%30543% | 6.3r10−10.2%199% | 7.0−14.3%20576% | 8.2−21.8%5669% | 10r12−25.7%2891% | 14r−14—813% | −12r12−227%−879% | 9.7—688% | |
| Operating income | −24—−18478% | −17—−30443% | −3.1r−9.9—−99.2% | −7.0—−20515% | −7.9—−5509% | −10r−11—−2798% | −13—−727% | −11—−806% | −6.7—−475% | |
| Interest expense and finance costs | 0.2−59.5%164% | 0.5−89.3%939% | 4.9+46.9%155% | 3.3+204%9809% | 1.1—762% | — | — | — | — | |
| Other non-operating income (expense) | 4.8−17.4%3712% | 5.8−30.4%10430% | 8.4r−4.9—266% | −3.5—−10432% | −0.6—−451% | −0.3r−0.5−193%−82.8% | 0.3−90.8%18.7% | 3.5+13415%252% | 0.0—1.9% | |
| Income before tax | −19—−14767% | −11r−11−313%−20013% | 5.3r15−49.8%167% | 11+20.7%30882% | 8.7r−8.7—6042% | −11—−3082% | −12—−708% | −7.7—−554% | — | |
| Income tax | 0.0—13.8% | 0—0.0% | 0—0.0% | — | — | −0.2−201%−41.6% | 0.1—8.6% | — | — | |
| Income from continuing operations | — | — | — | −10—−30771% | −8.6—−5958% | −10—−2879% | — | — | — | |
| Income from discontinued operations | — | — | — | — | −0.1—−71.5% | −0.7—−201% | — | — | — | |
| Net income including minority interests | −19—−14781% | −11−313%−20013% | 5.3r−15—167% | −11—−30947% | −8.7—−6031% | −11—−3040% | −12—−717% | −7.7—−554% | −6.6—−473% | |
| Minority interests' share of net income | −0.0—−25.4% | −0.1—−118% | 0r−0.0—0.0% | −0.1—−176% | −0.0—−2.1% | −0.1—−30.7% | −0.2—−13.3% | −0.2—−16.4% | −0.1—−4.1% | |
| Net income attributable to shareholders | −19—−14755% | −11−311%−19895% | 5.3r−15—167% | −10—−30771% | −8.7—−6024% | −11—−3010% | −12—−703% | −7.5—−537% | −6.6—−469% | |
| Earnings per share, basic | -1.91—— | -1.51−164%— | 2.36r-13.72—— | -9.70r-0.28—— | -0.23—— | -0.29—— | -0.33—— | -0.21—— | -0.21—— | |
| Earnings per share, diluted | -1.91—— | -1.51−307%— | 0.73r-13.72—— | -9.70—— | -0.23—— | -0.29—— | -0.33—— | -0.21—— | -0.21—— | |
| Shares, weighted average (basic) | 10+38.5%— | 7.4+229%— | 2.2r0.0+207036%— | 0.0r38−100.0%— | 38—— | — | — | — | — | |
| Shares, weighted average (diluted) | 10+38.5%— | 7.4+0.1%— | 7.4r0.0+681179%— | 0.0−100.0%— | 38+0.6%— | 38+1.1%— | 37+6.8%— | 35+13.9%— | 31—— | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 3.1−16.8%44.0% | 3.7−51.8%54.6% | 7.6r0.3+1081%85.0% | 0.6+10.4%19.9% | 0.6+10.8%18.5% | 0.5−77.6%13.4% | 2.4−64.9%31.6% | 6.7−9.1%62.9% | 7.4—76.6% | |
| Receivables | — | — | 0.1+1325%0.6% | 0.0−84.0%0.1% | 0.0−92.3%0.8% | 0.3−10.2%8.3% | 0.4+177%4.9% | 0.1+22.4%1.2% | 0.1—1.1% | |
| Other current assets | 0.3+301%4.4% | 0.1—1.1% | 0r0.4−100%0.0% | 1.8+11.0%55.7% | 1.6+13.6%51.5% | 1.4+6.8%36.4% | 1.3+31.9%18.0% | 1.0+814%9.5% | 0.1—1.2% | |
| Current assets | 6.1+7.1%87.5% | 5.7−25.5%84.4% | 7.6r0.8+211%85.0% | 2.5+9.8%75.7% | 2.2−2.1%70.8% | 2.3−43.7%58.2% | 4.1−48.4%54.5% | 7.9+3.4%73.6% | 7.6—78.8% | |
| Property, plant and equipment | 0.5−7.2%6.7% | 0.5−12.6%7.5% | 0.6—6.4% | — | — | — | 1.1+1151%15.1% | 0.1−30.2%0.8% | 0.1—1.3% | |
| Right-of-use (leased) assets | 0.4−18.2%5.4% | 0.5−30.8%6.9% | 0.7—7.4% | — | — | — | 0.7—9.8% | — | — | |
| Other intangible assets | — | — | 0r0.6−100%0.0% | 0.7−15.2%22.8% | 0.9−45.4%27.6% | 1.6−26.0%40.6% | 2.2−20.6%28.9% | 2.7+44.6%25.4% | 1.9—19.5% | |
| Total assets | 7.0+3.4%100% | 6.7−25.0%100% | 9.0r12+177%100% | 3.2+2.8%100% | 3.2−19.6%100% | 3.9−47.3%100% | 7.4−30.3%100% | 11+10.8%100% | 9.6—100% | |
| Accounts payable | 1.9+160%27.8% | 0.7+28.3%11.1% | 0.6r1.4+2.1%6.5% | 0.6+194%17.5% | 0.2−74.6%6.1% | 0.8+81.2%19.4% | 0.4+180%5.6% | 0.2+100%1.4% | 0.1—0.8% | |
| Current liabilities | 3.6+50.6%51.3% | 2.4+67.4%35.2% | 1.4r5.9−86.0%15.8% | 10+12.4%311% | 9.0+67.4%284% | 5.4+62.5%136% | 3.3+35.1%44.3% | 2.4—22.9% | — | |
| Lease liabilities (non-current) | 0.2−26.9%2.8% | 0.3−41.9%4.0% | 0.5—5.1% | — | — | — | — | — | — | |
| Total liabilities | 7.0+12.4%101% | 6.2+28.0%92.4% | 4.9r6.6−76.4%54.2% | 21+36.8%634% | 15+61.2%477% | 9.3+93.2%237% | 4.8+97.7%64.8% | 2.4+86.0%22.9% | 1.3—13.6% | |
| Retained earnings | −64—−914% | −44—−659% | −33r−131—−370% | −116—−3586% | −106—−3353% | −97—−2473% | −86—−1158% | −74—−694% | −67—−691% | |
| Shareholders' equity | −0.0−106%−0.5% | 0.6—9.5% | −32r5.5—−360% | −38r−17—−1166% | −12—−375% | −5.1−331%−130% | 2.2−70.2%29.8% | 7.4+2.3%69.8% | 7.3—75.6% | |
| Minority interests | 0—0.0% | −0.1—−2.0% | 0r−0.1—0.0% | −0.1—−3.2% | −0.0—−1.4% | −0.3−170%−7.1% | 0.4−49.1%5.4% | 0.8−24.5%7.3% | 1.0—10.8% | |
| Total equity | −0.0−107%−0.5% | 0.5—7.6% | −32r5.4—−360% | −38r−17—−1166% | −12—−377% | −5.4−306%−137% | 2.6−68.2%35.2% | 8.2−1.1%77.1% | 8.3—86.4% | |
| Total liabilities and equity | 7.0+3.4%100% | 6.7−25.0%100% | 9.0r12+177%100% | 3.2+2.8%100% | 3.2−19.6%100% | 3.9−47.3%100% | 7.4−30.3%100% | 11+10.8%100% | 9.6—100% | |
| Shares outstanding | 11+14.3%— | 9.4+291%— | 2.4r1.1+123%— | 1.1r38−97.2%— | 38+0.7%— | 38r38+0.1%— | 38+5.1%— | 36+6.2%— | 34—— | |
| Cash-flow statement | ||||||||||
| Depreciation and amortization | 0.10.0%76.9% | 0.1r0.2+11.1%179% | 0.1—2.9% | — | — | 0.7r1.1+77.9%194% | 0.4+578%22.7% | 0.1—4.2% | — | |
| Share-based compensation | 3.8+46.2%2918% | 2.6+10280%4634% | 0.0r0.6−96.7%0.8% | 0.8−23.9%2235% | 1.0+9.9%694% | 0.9r0.9−52.3%252% | 1.9+48.4%110% | 1.3+1027%92.0% | 0.1—8.1% | |
| Cash from operating activities | −18—−13812% | −17—−30602% | −2.5r−7.8—−78.5% | −5.9—−17468% | −7.9—−5455% | −7.8—−2165% | −10—−588% | −8.0—−573% | −6.3—−448% | |
| Capital expenditure | −0.1—−45.4% | −0.0—−39.3% | −0.5—−16.0% | — | — | −0.0—−5.5% | −0.6—−37.1% | −0.0—−1.5% | −0.0—−0.1% | |
| Cash from investing activities | −0.1—−45.4% | −0.0—−39.3% | −0.5r−10—−16.0% | — | 0.7—463% | −0.0—−5.5% | −0.4−127%−20.9% | 1.3+26440%95.1% | 0.0—0.4% | |
| Debt issued | — | — | — | — | — | 0.4—120% | — | — | — | |
| Shares issued | — | — | — | — | 0.5—344% | — | — | 5.0−50.0%358% | 10—712% | |
| Cash from financing activities | 17+31.8%13394% | 13+31.2%23593% | 10r18+67.8%319% | 6.0−17.2%17647% | 7.2+21.6%5032% | 6.0−4.9%1651% | 6.3+4.4%363% | 6.0−54.8%430% | 13—946% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | 0.1—8.6% | |
| Change in cash | −0.6—−474% | −3.9−156%−7048% | 7.1r−0.3+11518%225% | 0.1+7.0%179% | 0.1—39.6% | −1.9—−519% | −4.3—−246% | −0.7−109%−47.9% | 7.1—507% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 125—100% | 0−100%— | — | 130r0*—100% | 0−100%— | 130+155%100% | 0−100%— | — | 14—100% | 51—100% | 5.0—100% | 3,087r56*—100% | |
| Cost of revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1.0*—0.0% | |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | 55*—1.8% | |
| Research and development | 15,043+24.1%— | 4,627+26.7%3702% | 3,816+21.1%— | 3,199+8.4%— | 3,401*+43.8%2616% | 3,651+51.2%— | 3,152+97.7%2425% | 2,951+167%— | 2,365*+161%— | 2,415—17250% | 1,594—3125% | 1,106—22120% | 907r182*—29.4% | |
| General and administrative | 12,214+7.5%— | 3,359+22.5%2687% | 2,968+16.7%— | 3,081+6.0%— | 2,806*−11.5%2158% | 2,741−5.8%— | 2,543+9.5%1956% | 2,907+138%— | 3,170*+63.5%— | 2,911—20793% | 2,323—4555% | 1,220—24400% | 1,939r3,433*—62.8% | |
| Operating expenses | 27,257+16.1%— | 7,986+24.9%6389% | 6,784+19.1%— | 6,280+7.2%— | 6,207*+12.1%4775% | 6,392+20.0%— | 5,695+45.4%4381% | 5,858+152%— | 5,535*+94.5%— | 5,326—38043% | 3,917—7680% | 2,326—46520% | 2,846r3,615*—92.2% | |
| Operating income | — | −7,861—−6289% | −6,784—— | — | −6,207*—−4775% | −6,392—— | −5,565—−4281% | −5,858—— | −5,549*−2402%— | −5,312—−37943% | −3,866—−7580% | −2,321—−46420% | 241r−3,487*—7.8% | |
| Interest expense and finance costs | 794+2381%— | 204+3300%163% | 203+2156%— | 189—— | 198*+1065%152% | 6.0−62.5%— | 9.0−97.1%6.9% | 0−100%— | 17*−90.3%— | 16—114% | 307r242—602% | 99—1980% | 176*—5.7% | |
| Other non-operating income (expense) | 2,661−43.8%— | −45−103%−36.0% | 428—— | −611−159%— | 2,889*+3.3%2222% | 1,797−73.2%— | −897−110%−690% | 1,036—— | 2,797*+245%— | 6,695—47821% | 9,043—17731% | −12,694r−7,116—−253880% | 810r29*—26.2% | |
| Income before tax | — | — | — | −6,891—— | — | — | — | −4,822—— | — | — | — | — | — | |
| Income tax | — | — | — | 7.0—— | — | — | — | 0—— | — | — | — | — | 0*—0.0% | |
| Net income including minority interests | −24,496—— | −7,906—−6325% | −6,356—— | −6,898—— | −3,336*—−2566% | −4,595−432%— | −6,462−225%−4971% | −4,822—— | −2,752*−362%— | 1,383—9879% | 5,177—10151% | −15,015—−300300% | 1,051r−3,458*—34.0% | |
| Minority interests' share of net income | 0—— | 0—0.0% | 0—— | 0—— | 0*—0.0% | −10—— | −14—−10.8% | −9.0—— | −12*—— | −27—−193% | −27—−52.9% | 0—0.0% | 0r−2.0*—0.0% | |
| Net income attributable to shareholders | −24,496—— | −7,906—−6325% | −6,356—— | −6,898—— | −3,336*—−2566% | −4,585−425%— | −6,448−224%−4960% | −4,813—— | −2,740*−361%— | 1,410—10071% | 5,204—10204% | −15,015r−9,437—−300300% | 1,051r−3,456*—34.0% | |
| Earnings per share, basic | — | -0.31—— | -0.55—— | -0.58—— | — | -0.45−381%— | -0.66−208%— | -0.49—— | — | 0.16—— | 0.61—— | -5.38r-3.38—— | — | |
| Earnings per share, diluted | — | -0.31—— | -0.55—— | -0.58—— | — | -0.45−446%— | -0.66−229%— | -0.49—— | — | 0.13—— | 0.51—— | -5.38r-3.38—— | — | |
| Shares, weighted average (basic) | 25+146%— | 25+146%— | 16+63.8%— | 12+23.5%— | — | 10+16.8%— | 10+17.5%— | 9.8+250%— | — | 8.9—— | 8.5r0.0—— | 2.8—— | — | |
| Shares, weighted average (diluted) | 25+146%— | 25+146%— | 16+63.8%— | 12+23.5%— | — | 10−3.8%— | 10−1.5%— | 9.8+250%— | — | 11—— | 10r0.0—— | 2.8—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 19,403—88.7% | 19,403+125%88.7% | 23,024+281%89.2% | 24,526+475%89.8% | 3,056−16.8%44.0% | 8,620+171%69.4% | 6,041−0.4%67.6% | 4,267−51.0%63.4% | 3,672−51.8%54.6% | 3,185—42.8% | 6,064—56.6% | 8,706—80.2% | 7,619r345—85.0% | |
| Receivables | — | — | — | — | — | — | — | — | — | — | — | 65—0.6% | 57—0.6% | |
| Other current assets | 107—0.5% | 107−37.1%0.5% | 0−100%0.0% | 333+122%1.2% | 309+301%4.4% | 170+18.9%1.4% | 177+8750%2.0% | 150−9.6%2.2% | 77—1.1% | 143—1.9% | 2.0—0.0% | 166—1.5% | 0r352—0.0% | |
| Current assets | 20,931—95.7% | 20,931+82.1%95.7% | 25,030+213%97.0% | 26,474+360%97.0% | 6,080+7.1%87.5% | 11,497+112%92.6% | 7,991−10.4%89.4% | 5,754−35.6%85.5% | 5,676−25.5%84.4% | 5,423—72.9% | 8,917—83.3% | 8,937—82.3% | 7,619r754—85.0% | |
| Property, plant and equipment | 466—2.1% | 466−19.7%2.1% | 482−18.0%1.9% | 472−2.5%1.7% | 465−7.2%6.7% | 580+11.8%4.7% | 588+8.9%6.6% | 484−14.2%7.2% | 501−12.6%7.5% | 519—7.0% | 540—5.0% | 564—5.2% | 573—6.4% | |
| Right-of-use (leased) assets | 394—1.8% | 394+26.3%1.8% | 277−23.5%1.1% | 328−20.4%1.2% | 377−18.2%5.4% | 312−38.7%2.5% | 362−35.6%4.0% | 412−34.3%6.1% | 461−30.8%6.9% | 509—6.8% | 562—5.2% | 627—5.8% | 666—7.4% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | 509—6.8% | 541—5.1% | 574—5.3% | 0r607—0.0% | |
| Total assets | 21,873—100% | 21,873+76.2%100% | 25,814+189%100% | 27,299+306%100% | 6,951+3.4%100% | 12,413+67.0%100% | 8,941−16.5%100% | 6,731−38.0%100% | 6,724−25.0%100% | 7,435—100% | 10,708—100% | 10,856—100% | 8,968r11,965—100% | |
| Accounts payable | 1,338—6.1% | 1,338−51.0%6.1% | 1,858+8.9%7.2% | 2,827+138%10.4% | 1,931+160%27.8% | 2,731—22.0% | 1,706+41.8%19.1% | 1,188−54.4%17.6% | 744+28.3%11.1% | — | 1,203—11.2% | 2,605—24.0% | 580r1,413—6.5% | |
| Current liabilities | 4,529—20.7% | 4,529−48.5%20.7% | 3,762+5.6%14.6% | 6,340+170%23.2% | 3,563+50.6%51.3% | 8,789−35.0%70.8% | 3,561−71.8%39.8% | 2,352−83.3%34.9% | 2,366+67.4%35.2% | 13,514—182% | 12,633—118% | 14,059—130% | 1,413r5,914—15.8% | |
| Lease liabilities (non-current) | 197—0.9% | 197+33.1%0.9% | 122−34.1%0.5% | 159−30.0%0.6% | 196−26.9%2.8% | 148−52.6%1.2% | 185−48.9%2.1% | 227−45.0%3.4% | 268−41.9%4.0% | 312—4.2% | 362—3.4% | 413—3.8% | 461—5.1% | |
| Total liabilities | 7,954—36.4% | 7,954−26.5%36.4% | 7,084−2.9%27.4% | 9,671+87.0%35.4% | 6,988+12.4%101% | 10,819−49.1%87.2% | 7,295−73.1%81.6% | 5,172−65.9%76.8% | 6,216+28.0%92.4% | 21,263—286% | 27,101—253% | 15,165—140% | 4,858r6,607—54.2% | |
| Retained earnings | −84,660—−387% | −84,660—−387% | −76,754—−297% | −70,398—−258% | −63,500—−914% | −60,164—−485% | −55,579—−622% | −49,131—−730% | −44,318—−659% | −41,578r−21,775—−559% | −42,988r−23,185—−401% | −48,192r−5,435—−444% | −33,177r−131,013—−370% | |
| Shareholders' equity | 13,919—63.6% | 13,919+691%63.6% | — | — | −37−106%−0.5% | 1,760—14.2% | 1,802—20.2% | 1,701—25.3% | 641—9.5% | −13,774—−185% | −16,363—−153% | −4,309—−39.7% | −32,294r5,469—−360% | |
| Minority interests | — | — | — | — | 0—0.0% | −166—−1.3% | −156—−1.7% | −142—−2.1% | −133—−2.0% | −54—−0.7% | −30—−0.3% | — | 0r−111—0.0% | |
| Total equity | 13,919—63.6% | 13,919+773%63.6% | 18,730+1038%72.6% | 17,628+1031%64.6% | −37−107%−0.5% | 1,594—12.8% | 1,646—18.4% | 1,559—23.2% | 508—7.6% | −13,828—−186% | −16,393—−153% | −28,388—−261% | −32,294r5,358—−360% | |
| Total liabilities and equity | 21,873—100% | 21,873+76.2%100% | 25,814+189%100% | 27,299+306%100% | 6,951+3.4%100% | 12,413+67.0%100% | 8,941−16.5%100% | 6,731−38.0%100% | 6,724−25.0%100% | 7,435—100% | 10,708—100% | 10,856—100% | 8,968r11,965—100% | |
| Shares outstanding | 26—— | 26+150%— | 25+150%— | 15+50.0%— | 11+14.3%— | 11+18.6%— | 10+15.4%— | 9.9+18.0%— | 9.4+291%— | 8.9—— | 8.8—— | 8.4—— | 2.4r1.1—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 61−30.7%— | 19*+18.8%15.2% | 18*+12.5%— | 0—— | 24*−57.1%18.5% | 16*−71.4%— | 16*−71.9%12.3% | 0r17−100%— | 56*+833%— | 56*—400% | 57*—112% | 25—500% | 6.0*—0.2% | |
| Share-based compensation | 4,146+8.2%— | 1,070+7.1%856% | 1,051+18.1%— | 1,077+12.7%— | 948*−4.0%729% | 999−8.9%— | 890+94.3%685% | 956+1704%— | 988*—— | 1,096—7829% | 458—898% | 53—1060% | 0r503*—0.0% | |
| Cash from operating activities | −22,780—— | −5,495*—−4396% | −6,684*—— | −4,568—— | −6,033*—−4641% | −3,850*—— | −3,750*—−2885% | −4,322—— | −4,589*−3893%— | −2,962*—−21157% | −8,009*—−15704% | −1,577—−31540% | 121r−2,052*—3.9% | |
| Capital expenditure | −56—— | −3.0*—−2.4% | −28*—— | −25—— | 0*—0.0% | −13*—— | −46*—−35.4% | 0—— | −5.0*—— | −3.0*—−21.4% | 0*—0.0% | −14—−280% | — | |
| Cash from investing activities | −56—— | −3.0*—−2.4% | −28*—— | −25—— | 0*—0.0% | −13*—— | −46*—−35.4% | 0—— | −5.0*—— | −3.0*—−21.4% | 0*—0.0% | −14—−280% | −70r0*—−2.3% | |
| Shares issued | — | — | — | — | — | — | — | 4,916—— | — | — | — | 0—0.0% | — | |
| Cash from financing activities | 33,622+53.1%— | 1,882*−70.8%1506% | 5,202*−6.6%— | 26,057+430%— | 481*−90.4%370% | 6,444*+7393%— | 5,570*+3.8%4285% | 4,917+80.2%— | 5,031*—— | 86*—614% | 5,367*—10524% | 2,728—54560% | −13r2,000*—−0.4% | |
| Change in cash | 10,783+100%— | −3,621*−240%−2897% | −1,502*−185%— | 21,470+3508%— | −5,564*−1373%−4280% | 2,579*—— | 1,774*—1365% | 595−47.7%— | 437*+1050%— | −2,879*—−20564% | −2,642*—−5180% | 1,137—22740% | 38r−52*—1.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Serina Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Grant revenues$0 M100%+117%
Business segments
- Reportable$0 M100%+117%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Serina Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $638 K | −$357 K | $545 K | $10 |
| 2024Chief executive | $3.7 M | $3.7 M | $1.7 M | $25 |
| 2023Chief executive | $1.1 M | $1.1 M | $300 K | $70 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Serina Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 5 · Material agreement 4 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 6 · Shareholder vote 2 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Serina Therapeutics, Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2020.
Lobbying firms hired in 2020
Bradley Arant Boult Cummings LLP
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2020 | $0 | — | 3 |
| 2019 | $0 | — | 4 |
| 2018 | $60 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Serina Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | · | · | · | 12 | · | · | · | · | · | · | · | · | 12 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 12 people | Restructuring planSEC 8-K | “The reduction in staffing is anticipated to affect 12 employees, primarily research and development personnel, and is expected to be completed on or around May 1, 2020.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Serina Therapeutics, Inc. compares in Biotechnology
- Market cap$50 M · higher than 26% of 726
- Revenue$0 M · higher than 17% of 647
- Revenue growth116.7% · higher than 84% of 438
- Price / sales386.3× · lower than 3% of 339
- FCF yield-35.9% · higher than 31% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Serina Therapeutics, Inc.🇺🇸 | $50 M | — | — | +116.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Serina Therapeutics, Inc.? Verify and update this profile — free
Show Serina Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.